SMT’s Supraflex stent clinically at par with Abbott’s Xience , with numerically better outcome:… Patients who got Supraflex stent had target lesion failure occur among 6.9 per cent at 720 days vs 7.9 per cent of Xience…
SMT announces CE* mark for Supraflex Cruz Being one of the most trackable stents globally, more than 2,50,000 people with coronary artery diseases have been treated with…
